Search bioRxiv⌕ Search

Biology subjects

Birgmeier, J.

Publications and source records attributed to Birgmeier, J..

7 recordsLinked to original sources

AMELIE 2 speeds up Mendelian diagnosis by matching patient phenotype & genotype to primary literature

The diagnosis of Mendelian disorders requires labor-intensive literature research. Trained clinicians can spend hours looking for the right publication/s supporting a single gene that best explains a patients disease. AMELIE (Automatic Mendelian Literature Evaluation) greatly accelerates this process. AMELIE parses all 29 million PubMed abstracts, downloads and further parses hundreds of thousands of full text articles in search of information supporting the causality and associated phenotypes of any published genetic variant. AMELIE then prioritizes patient candidate variants for their likelihood of explaining any patients given set of phenotypes. Diagnosis of singleton patients (without relatives exomes) is the most time-consuming scenario. AMELIE ranked the causative gene at the very top in 2/3 of 215 diagnosed singleton Mendelian patients. Evaluating only the top 11 AMELIE scored genes of 127 (median) candidate genes per patient results in rapid diagnosis for 90+% of cases. AMELIE-based evaluation of all cases is 3-19x more efficient than hand-curated database-based approaches. We replicate these results on a cohort of clinical cases from Stanford Childrens Health and the Manton Center for Orphan Disease Research. An analysis web portal with our most recent update, programmatic interface and code will be available at AMELIE.stanford.edu. A pilot run of the web portal has already served many thousands of job submissions from dozens of countries.

genetics↗

Keeping patient phenotypes and genotypes private while seeking disease diagnoses

In an age where commercial entities are allowed to collect and directly profit from large amounts of private information, an age where large data breaches of such organizations are discovered every month, science must strive to offer society viable ways to preserve privacy while benefitting from the power of data sharing. Patient phenotypes and genotypes are critical for building groups of phenotypically-similar patients, identify the gene that best explains their common phenotypes, and ultimately, diagnose a patient with a Mendelian disease. Direct computation over these quantities requires highly-sensitive patient data to be shared openly, compromising patient privacy and opening patients up for discrimination. Existing protocols focus on secure computation over genotype data and only address the final steps of the disease-diagnosis pipeline where phenotypically-similar patients have been identified. However, identifying such patients in a secure and private manner remains open. In this work, we develop secure protocols to maintain patient privacy while computing meaningful operations over both genotypic and phenotypic data for two real scenarios: COHORT DISCOVERY and GENE PRIORITIZATION. Our protocols newly enable a complete and secure end-to-end disease diagnosis pipeline that protects sensitive patient phenotypic and genotypic data.

genomics↗

Differential chromatin accessibility in developing projection neurons is correlated with transcriptional regulation of cell fate

We are only just beginning to catalog the vast diversity of cell types in the cerebral cortex. Such categorization is a first step toward understanding how diversification relates to function. All cortical projection neurons arise from a uniform pool of progenitor cells that lines the ventricles of the forebrain. It is still unclear how these progenitor cells generate the more than fifty unique types of mature cortical projection neurons defined by their distinct gene expression profiles. Here we compare gene expression and chromatin accessibility of two subclasses of projection neurons with divergent morphological and functional features as they develop in the mouse brain between embryonic day 13 and postnatal day 5 in order to identify transcriptional networks that diversity neuron cell fate. We find groups of transcription factors whose expression is correlated with chromatin accessibility, transcription factor binding motifs, and lncRNAs that define each subclass and validate the function of a family of novel candidate genes in vitro. Our multidimensional approach reveals that subclass-specific chromatin accessibility is significantly correlated with gene expression, providing a resource for generating new specific genetic drivers and revealing regions of the genome that are particularly susceptible to harmful genetic mutations by virtue of their correlation with important developmental genes.

developmental biology↗

AVADA Enables Automated Genetic Variant Curation Directly from the Full Text Literature

PurposeThe primary literature on human genetic diseases includes descriptions of pathogenic variants that are essential for clinical diagnosis. Variant databases such as ClinVar and HGMD collect pathogenic variants by manual curation. We aimed to automatically construct a freely accessible database of pathogenic variants directly from full-text articles about genetic disease.\n\nMethodsAVADA (Automatically curated VAriant DAtabase) is a novel machine learning tool that uses natural language processing to automatically identify pathogenic variants and genes in full text of primary literature and converts them to genomic coordinates for rapid downstream use.\n\nResultsAVADA automatically curated almost 60% of pathogenic variants deposited in HGMD, a 4.4-fold improvement over the current state of the art in automated variant extraction. AVADA also contains more than 60,000 pathogenic variants that are in HGMD, but not in ClinVar. In a cohort of 245 diagnosed patients, AVADA correctly annotated 38 previously described diagnostic variants, compared to 43 using HGMD, 20 using ClinVar and only 13 (wholly subsumed by AVADA and ClinVars) using the best automated abstracts-only based approach.\n\nConclusionAVADA is the first machine learning tool that automatically curates a variants database directly from full text literature. AVADA is available upon publication at http://bejerano.stanford.edu/AVADA.

genetics↗

ClinPhen extracts and prioritizes patientphenotypes directly from medical records to accelerate genetic disease diagnosis

PurposeSevere genetic diseases affect 7 million births per year, worldwide. Diagnosing these diseases is necessary for optimal care, but it can involve the manual evaluation of hundreds of genetic variants per case, with many variants taking an hour to evaluate. Automatic gene-ranking approaches shorten this process by reporting which of the genes containing variants are most likely to be causing the patients symptoms. To use these tools, busy clinicians must manually encode patient phenotypes, which is a cumbersome and imprecise process. With 60 million patients expected to be sequenced in the next 7 years, a fast alternative to manual phenotype extraction from the clinical notes in patients medical records will become necessary.\n\nMethodsWe introduce ClinPhen: a fast, high-accuracy tool that automatically converts the clinical notes into a prioritized list of patient symptoms using HPO terms.\n\nResultsClinPhen shows superior accuracy to existing phenotype extractors, and when paired with a gene-ranking tool it significantly improve the latters performance.\n\nConclusionCompared to manual phenotype extraction, ClinPhen saves more than 5 hours per case in Mendelian diagnosis alone. Summing over millions of forthcoming cases whose medical notes await phenotype encoding, ClinPhen makes a substantial contribution towards ending all patients diagnostic odyssey.

genomics↗

Phrank measures phenotype sets similarity to greatly improve Mendelian diagnostic disease prioritization

PurposeExome sequencing and diagnosis is beginning to spread across the medical establishment. The most time-consuming part of genome based diagnosis is the manual step of matching the potentially long list of patient candidate genes to patient phenotypes to identify the causative disease.\n\nMethodsWe introduce Phrank (for phenotype ranking), an information-theory inspired method that utilizes a Bayesian Network to prioritize candidate diseases or genes, as a stand-alone module that can be run with any underlying knowledgebase and any variant filtering scheme.\n\nResultsPhrank outperforms existing methods at ranking the causative disease or gene when applied to 169 real patient exomes with Mendelian diagnoses. Phranks greatest improvement is in disease space, where across all 169 patients it ranks only 3 diseases on average ahead of the true diagnosis, whereas Phenomizer ranks 32 diseases ahead of the causal one.\n\nConclusionUsing Phrank to rank all patient candidate genes or diseases, as they start working through a new case, will save the busy clinician much time in deriving a genetic diagnosis.

genomics↗

AMELIE accelerates Mendelian patient diagnosis directly from the primary literature

The diagnosis of Mendelian disorders requires labor-intensive literature research. Our software system AMELIE (Automatic Mendelian Literature Evaluation) greatly automates this process. AMELIE parses hundreds of thousands of full text articles to find an underlying diagnosis to explain a patients phenotypes given the patients exome. AMELIE prioritizes patient candidate genes for their likelihood of causing the patients phenotypes. Diagnosis of singleton patients (without relatives exomes) is the most time-consuming scenario. AMELIEs gene ranking method was tested on 215 singleton Mendelian patients with a clinical diagnosis. AMELIE ranked the causal gene among the top 2 in the majority (63%) of cases. Examining AMELIEs top 10 genes, amounting to 8% of 124 candidate genes with rare functional variants per patient, results in diagnosis for 95% of cases. Strikingly, training only on gene pathogenicity knowledge from 2011 leads to identical performance compared to training on current data. An accompanying analysis web portal has launched at AMELIE.stanford.edu.

genetics↗